ArticleAmerican heart journal plus : cardiology research and practice2026
Retrospective comparision of embolization and conservative therapy for pulmonary artery pseudoaneurysm.
Article in American heart journal plus : cardiology research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare the efficacy and prognosis of endovascular treatments (support auxiliary spring coil embolization (SASCE) and coil embolization alone) versus medical therapy for pulmonary artery pseudoaneurysm (PAP), and to provide optimized treatment and management strategies for clinical practice. Methods: Data from PAP patients who received endovascular or medical therapy at our hospital between 2016 and 2022 were retrospectively collected. Univariate and multivariate binary logistic regression analyses were performed; forest plots and Kaplan-Meier survival curves were generated to illustrate differences between groups. Results: A total of 148 PAP patients (90 males, 58 females; mean age 59.60 ± 12.60 years) were enrolled. Underlying diseases: pulmonary tuberculosis ( Conclusion: Compared with medical therapy, endovascular embolization shows potential advantages in improving progression-free survival (PFS) and reducing the risk of hemoptysis recurrence and death. SASCE appeared numerically better than coil embolization alone, but the difference was not statistically significant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.